Navigation Links
CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
Date:6/9/2010

DURHAM, N.C., June 9 -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the selection of doses for pivotal Phase III studies of lasmiditan in the acute treatment of migraine, scheduled to begin in fourth quarter this year.

"There is a high unmet need for novel migraine treatments that are effective and safe," said James F. White, Ph.D., President and Chief Executive Officer of CoLucid. "Currently available drugs have varying efficacy and side effects that limit their use in patients. Lasmiditan with its exciting new mechanism of action has the potential to address these patient needs."

In the recently completed double blind, randomized, placebo-controlled parallel group dose-ranging study conducted in five European countries, 391 patients treated a single migraine attack with one of four doses of lasmiditan or placebo. The Phase IIb study met its primary endpoint, showing a highly significant correlation between dose and headache relief at two hours. Individual doses showed significant benefit compared to the placebo from as early as 30 minutes after treatment. Lasmiditan also provided significant relief of other migraine symptoms, as measured in the study, including nausea, photophobia and phonophobia.

Dizziness and fatigue were the most common adverse events reported in the study. No clinically significant adverse effects were identified in either the laboratory parameters or electrocardiography (ECGs). Cardiovascular adverse events, including chest symptoms experienced with the current migraine medication group known as triptans, wer
'/>"/>

Contact: Shirley Chow
Shirley.chow@porternovelli.com
212-601-8308
Porter Novelli
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
2. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
3. LaserCard Corporation Announces Expansion of Middle East Project
4. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
5. Balzan Foundation announces 2007 winners
6. The American Society of Plant Biologists announces 2007 awards
7. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
8. NIST announces 56 new awards for innovative technology research and development
9. Titanium Group Announces Contract With Haitong Securities
10. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
11. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2014)... study published in Cancer Research shows SIRT6—a ... colon cancers—can promote the development of skin cancers by ... survival of sun-damaged skin cells. , Previously considered protective, ... called sirtuins that help regulate genomic stability and prevent ... helps repair DNA damage, which can lead to cancer. ...
(Date:10/14/2014)... leading questions is how to produce enough food to ... Food and Agriculture Organization of the United Nations predicts ... 40 years to feed a growing global population, and ... in food production. Plants—grains, cereals, fruits, vegetables, and ... Current research must tap into our knowledge of how ...
(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... to Research Careers) Program has announced the travel award recipients ... in Los Angeles, CA from June 26-30, 2013. These awards ... scientists from underrepresented groups into the mainstream of the basic ... at the GSA: 19th International C. elegans Meeting. ...
... FASEB MARC (Maximizing Access to Research Careers) Program ... for the Study of Reproduction meeting in Montreal, Canada ... promote the entry of students, postdoctorates and scientists from ... community and to encourage the participation of young scientists ...
... of households could go a long way to reducing greenhouse ... in energy demands at the household level, appears in the ... Saner and colleagues point out that the energy people use ... accounts for more than 70 percent of emissions of carbon ...
Cached Biology News:
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... CAMBRIDGE, Mass. , Oct. 19, 2014 NextCODE ... of the whole genome in real time, today announced the ... the NextCODE Exchange , at the American Society of ... . To learn more, sign up and apply for ... on its unique features and benefits can be viewed ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Abstract , ... with differing surface treatment procedures and carbon content levels , ... , Introduction ... been , made commercially available that offer optimized properties for ...
... , Dr. Karl-Heinz Esser, multiBIND biotec GmbH, ... AppliChem GmbH and, , ... , , , ... gene technology demonstrate,that even small amounts of free DNA molecules,are sufficient to cause ...
... Recommended Cecil Instrumentation: , Cecil Adept HPLC ... Fraction collector , Column heater, ... Researchers need to understand the expression of proteins. ... diseased cells. , Hence the study of proteomics, which ...
Cached Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3New Insights Into DNA Decontamination 2New Insights Into DNA Decontamination 3New Insights Into DNA Decontamination 4New Insights Into DNA Decontamination 5Semi Preparative Purification of Proteins 2
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
Biology Products: